TCRX

Price & events

Pipeline stages · 3 programs

Pipeline · 3 trials · 2 upcoming

Catalyst news & presentations · 13

• this monthtrial initiationsecondaryPhase 3TSC-101 · First patient enrollment in pivotal Phase 3 ALLOHA-2 studySEC 8-K
• H1 2026conferencedata presentationsecondarysolid tumor program · Clinical and preclinical data from solid tumor program expected.SEC 8-K
• 1Q26readoutPhase 1Solid tumor TCR-T (multiplex) · Safety and response data for multiplex TCR-T therapySEC 8-K
• Q1 2026readoutPhase 1PLEXI-T · Initial safety and efficacy data from PLEXI-T trial.SEC 8-K
• Q1 2026regulatory submissionFiled (NDA/BLA)TSC-102 · File two INDs for TSC-102 (HLA-A*03:01 and A*01:01).SEC 8-K
• YE25readoutPhase 1TSC-100, TSC-101 · Two-year relapse data on initial Phase 1 patientsSEC 8-K
• 2H25trial initiationsecondaryTSC-100, TSC-101 · Launch pivotal study in heme malignanciesSEC 8-K
• Q4 2025regulatory submissionFiled (NDA/BLA)heme program (two new IND candidates) · IND applications for two additional HLA-targeted TSC candidates.SEC 8-K
• 2025-11-03trial discontinuedPLEXI-T · Paused further enrollment in solid tumor Phase 1 trial to prioritize heme program.SEC 8-K
• 2025-11-03fda agreementTSC-101 · FDA agreed on pivotal trial design with internal control arm for TSC-101 in AML/MDS after HCT.SEC 8-K
• 2024-12-26partnershipOffering expected to close on or about December 27, 2024; net proceeds ~$29.8M for general corporate purposesSEC 8-K
• 2024-12-26partnershipEntered securities purchase agreement for registered direct offering of pre-funded warrants to purchase up to 7.5M shares of voting common stock at $4.00 per warrant, aggregate gross proceeds ~$30MSEC 8-K
• December 9, 2024 at ASH Annual Meetingconferencedata presentationsecondaryPhase 1TSC-100, TSC-101 · Oral presentation of updated Phase 1 ALLOHA trial data at ASH.SEC 8-K